Mural Oncology, Inc clinical trials
Formerly part of Alkermes, Inc., Nov 15, 2023 · source ↗
The registry lists 6 studies whose lead sponsor is Mural Oncology, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 28, 2025.
Before and after it left Alkermes, Inc.
- First submitted before Mural Oncology, Inc left Alkermes, Inc.
- 6
- First submitted after Mural Oncology, Inc left Alkermes, Inc.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Mural Oncology, Inc6 studies
Something wrong with this grouping? Tell us on the Alkermes, Inc. page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Alkermes, Inc. studies →
- Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)TerminatedNCT05092360Phase 3
Sponsor listed in the registry: Mural Oncology, Inc · First submitted before Mural Oncology, Inc left Alkermes, Inc.
- Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6TerminatedNCT04830124Phase 2
Sponsor listed in the registry: Mural Oncology, Inc · First submitted before Mural Oncology, Inc left Alkermes, Inc.
- A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid TumorsCompletedNCT02799095Phase 1/2
Sponsor listed in the registry: Mural Oncology, Inc · First submitted before Mural Oncology, Inc left Alkermes, Inc.
- A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck CancerCompletedNCT04144517Phase 2
Sponsor listed in the registry: Mural Oncology, Inc · First submitted before Mural Oncology, Inc left Alkermes, Inc.
- Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)Active, not recruitingNCT04592653Phase 1/2
Sponsor listed in the registry: Mural Oncology, Inc · First submitted before Mural Oncology, Inc left Alkermes, Inc.
- A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)CompletedNCT03861793Phase 1/2
Sponsor listed in the registry: Mural Oncology, Inc · First submitted before Mural Oncology, Inc left Alkermes, Inc.